Analyst Reco. Vanda Pharmaceuticals Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			5-day change	1st Jan Change
7.220 ^USD	-1.50%		+3.14%	-18.14%

04-09	Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines	MT
04-08	Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects	MT

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
02-25	B. Riley Adjusts Vanda Pharmaceuticals Price Target to $17 From $14, Maintains Buy Rating	MT
12-31	B. Riley Raises Price Target on Vanda Pharmaceuticals to $14 Form $11, Keeps Buy Rating	MT
11-05	B. Riley Initiates Coverage on Vanda Pharmaceuticals With Buy Rating, $11 Price Target	MT
31/07/25	Vanda Pharmaceuticals Q2 revenue up 4%	RE
31/10/24	HC Wainwright Starts Vanda Pharmaceuticals With Buy Rating, $18 Price Target	MT
11/07/24	Cantor Fitzgerald Initiates Vanda Pharmaceuticals at Overweight With $11 Price Target	MT
27/06/24	The same old winners
25/02/22	Jefferies Downgrades Vanda Pharmaceuticals to Hold From Buy, Adjusts Price Target to $12 From $24	MT
12/05/21	VANDA PHARMACEUTICALS : BofA Securities Starts Vanda Pharmaceuticals at Buy With $22 Price Target	MT
14/01/21	VANDA PHARMACEUTICALS : Citigroup Downgrades Vanda Pharmaceuticals to Neutral From Buy; Price Target is $14	MT